Intech Investment Management LLC Has $2.30 Million Stock Holdings in TransMedics Group, Inc. $TMDX

Intech Investment Management LLC trimmed its holdings in shares of TransMedics Group, Inc. (NASDAQ:TMDX) by 34.8% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 18,913 shares of the company’s stock after selling 10,114 shares during the period. Intech Investment Management LLC owned about 0.06% of TransMedics Group worth $2,301,000 at the end of the most recent quarter.

A number of other large investors also recently modified their holdings of the business. Foundations Investment Advisors LLC boosted its stake in shares of TransMedics Group by 60.4% during the 4th quarter. Foundations Investment Advisors LLC now owns 4,182 shares of the company’s stock worth $509,000 after buying an additional 1,575 shares during the last quarter. Geode Capital Management LLC boosted its stake in shares of TransMedics Group by 0.4% during the 4th quarter. Geode Capital Management LLC now owns 816,474 shares of the company’s stock worth $99,339,000 after buying an additional 2,903 shares during the last quarter. Annis Gardner Whiting Capital Advisors LLC boosted its stake in shares of TransMedics Group by 70.5% during the 4th quarter. Annis Gardner Whiting Capital Advisors LLC now owns 2,636 shares of the company’s stock worth $321,000 after buying an additional 1,090 shares during the last quarter. SLT Holdings LLC boosted its stake in shares of TransMedics Group by 62.4% during the 4th quarter. SLT Holdings LLC now owns 4,099 shares of the company’s stock worth $499,000 after buying an additional 1,575 shares during the last quarter. Finally, Hantz Financial Services Inc. boosted its stake in shares of TransMedics Group by 196.2% during the 4th quarter. Hantz Financial Services Inc. now owns 311 shares of the company’s stock worth $38,000 after buying an additional 206 shares during the last quarter. 99.67% of the stock is currently owned by institutional investors and hedge funds.

TransMedics Group Stock Up 1.8%

Shares of TMDX stock opened at $69.69 on Thursday. The company has a debt-to-equity ratio of 1.70, a quick ratio of 6.19 and a current ratio of 6.74. The firm’s 50-day moving average is $90.24 and its 200-day moving average is $117.59. The stock has a market cap of $2.41 billion, a price-to-earnings ratio of 15.84 and a beta of 1.91. TransMedics Group, Inc. has a 52-week low of $60.10 and a 52-week high of $156.00.

TransMedics Group (NASDAQ:TMDX) last issued its earnings results on Tuesday, May 5th. The company reported $0.30 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.62 by ($0.32). The firm had revenue of $173.93 million during the quarter, compared to the consensus estimate of $174.44 million. TransMedics Group had a net margin of 27.04% and a return on equity of 22.38%. The firm’s revenue for the quarter was up 21.2% compared to the same quarter last year. During the same period in the previous year, the company posted $0.70 earnings per share. Sell-side analysts predict that TransMedics Group, Inc. will post 1.98 EPS for the current year.

Analyst Upgrades and Downgrades

A number of equities analysts have recently commented on the stock. Canaccord Genuity Group reduced their price objective on shares of TransMedics Group from $152.00 to $124.00 and set a “buy” rating for the company in a research note on Wednesday, May 6th. TD Cowen reduced their price objective on shares of TransMedics Group from $190.00 to $120.00 and set a “buy” rating for the company in a research note on Wednesday, May 6th. Piper Sandler reduced their price objective on shares of TransMedics Group from $160.00 to $120.00 and set an “overweight” rating for the company in a research note on Wednesday, May 6th. Wall Street Zen downgraded shares of TransMedics Group from a “hold” rating to a “sell” rating in a research note on Saturday, May 9th. Finally, Stifel Nicolaus reduced their price objective on shares of TransMedics Group from $85.00 to $75.00 and set a “hold” rating for the company in a research note on Tuesday, May 26th. Six investment analysts have rated the stock with a Buy rating and seven have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus price target of $134.00.

TransMedics Group Profile

TransMedics Group, Inc is a medical device company headquartered in Andover, Massachusetts, that specializes in advanced organ preservation and transport systems for transplantation. The company’s flagship technology, the Organ Care System (OCS), maintains donor organs in a near-physiologic, warm, beating state during transportation, with the aim of extending preservation times and improving post‐transplant outcomes. TransMedics’ solutions address a critical need in transplantation by reducing ischemic injury and expanding the donor organ pool.

TransMedics currently markets two commercially available OCS platforms.